¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Antisense research and development."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • bilateral cleft lip and palate
    ¾çÂÊÀÔ¼úÀÔõÀå°¥¸²Áõ
  • bread and butter pericarditis
    »§¹öÅ͸ð¾ç½ÉÀ帷¿°
  • dilatation and curettage
    ÀڱøñÈ®Àå±Ü¾î³¿¼ú, °æ°üÈ®ÀåÀÚ±Ã¼ÒÆÄ¼ú
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⸸¼º¿ø¹Ýż±ÇǺο°
  • foot-and-mouth disease
    ÀԹ߱Áº´, ±¸Á¦¿ª
  • incision and drainage
    Àý°³¹è³ó
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • embryonal and botryoid rhabdomyosarcoma
    ¹è¾ÆÆ÷µµÈ¾¹®±ÙÀ°Á¾
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • intake and output record
    ¼·Ãë¹è¼³·®±â·Ï
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • law of weights and measures
    °è·®¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • glycerin and potash solution
    ±Û¸®¼¼¸° Ä®·ý¾×.
  • gray matter (nuclei and columns)
    ȸ»öÁú(½Å°æÇÙ°ú ½Å°æ±âµÕ)
  • half and half nail
    ¹Ý¹Ý Á¶°©
  • hand and foot disease
    ¼ö Á· Áúȯ£¨â¢ðëòðü´£©£¬¼Õ ¹ß º´, ¼ö Á· º´ (â¢ðëÜ»).
  • hand foot and mouth disease
    ¼Õ¹ßÀÔº´ (¡­Ü»), ¼öÁ·±¸º´(â¢ðëϢܻ).
  • hand foot and mouth disease
    ¼Õ¹ßÀÔº´ (¡­Ü»), ¼öÁ·±¸º´(â¢ðëϢܻ)
  • heat and acetic acid test
    °¡¿Â¾Æ¼¼Æ®»ê½ÃÇè (¹ý)(ʥ计­ß«ãËúÐÛö).
  • hereditary motor and sensory neuropathy
    À¯Àü¼º¿îµ¿ °¨°¢½Å°æº´Áõ
  • incision and drainage
    Àý°³¹è³ó(ü°³¹è³ó).
  • personality, anxious and fearful
    ºÒ¾È°øÆ÷¼º ÀΰÝ
  • pharmacy and therapeutic committee
    ¾à»çÀÇ·áÀ§¿øÈ¸(ËâË×ËöËíËôËôÌ·) º´¿ø(ËÓ Ëô)ÀÇ .
  • pneumocyte, types i and ii
    ÆóÆ÷¼¼Æ÷(øËøàá¬øà), IÇü°ú IIÇü
  • porokeratotoic eccrine ostial and dermal duct nevus
    ÇѰø°¢È­Áõ¼º ¿¡Å©¸°±¸¸Û ¹× ÁøÇǰü¸ð¹Ý
  • positional and postural vertigo
    µÎÀ§ ¹× üÀ§ º¯È¯(¼º) Çö±â
  • pruritic urticarial papules and plaqes of pregnany
    ÀӽŠ¼Ò¾ç¼º µÎµå·¯±â¼º ±¸Áø ¹× ÆÇ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • prenatal development
    Ãâ»ýÀü¹ßÀ°(¡­Û¡ëÀ).
  • prescreening development questionnaire for Denver developmental screening test
  • primary bone development
    ÀÏÂ÷»À¹ß»ý
  • psychosexual development
    Á¤½Å¼º ¹ß´Þ.
  • psychosocial development
    Á¤½Å»çȸÀû ¹ß´Þ
  • self-help, development
    ÀÚÁ¶(¹ß´Þ¿¡¼­)
  • sensory development
    °¨°¢<Áö°¢>¹ß´Þ (¡­Û¡Ó¹).
  • sexual development
    ¼º¹ß´Þ
  • various kind of obstacles of development
    °¢Á¾¼ºÀåÀå¾Ö(¡­î¡äô).
  • various kind of obstacles of development
    °¢Á¾¼ºÀåÀå¾Ö(¡­î¡äô)
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • alternate hot and cold caloric examination
    ³Ã¿Â±³´ë(¿Âµµ)Àڱذ˻ç(ÕÒè®Îßû»è®öôô§Ð½ËþÞÛ).
  • ambient temperature and pressure saturated with water vapor =ATP
    ½Ç¿Â´ë±â¾Ð ¼öÁõ±â Æ÷È­»óÅÂ
  • american society of therapeutic radiology and onco
    logy (ASTRO) ¹Ì±¹¹æ»ç¼±Á¾¾çÇÐȸ
  • aphasic and apraxic syndrome
    ½Ç¾î½ÇÇàÁõÈıº(ã÷åÞãùú¼ñøý¦ÏØ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ABC absolute basophil count; absolute bone conduction; acalculous biliary colic; acid balance control; a...
EGDF embryonic growth and development factor
ESHEL Association for Planning and Development of Services for the Aged in Israel
GD gastroduodenal; Gaucher disease; general diagnostics; general dispensary; gestational day; Gianotti ...
G&D growth and development
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ASO Antisense oligonucleotide
AS antisense S-oligonucleotide
AODN antisense oligodeoxynucleotide
AHCPR Agency for Health Care Policy and Research
AHRQ Agency for Health Care Research and Quality
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • connective tissue sheath of Key and Retzius
    Ű-·¹Ä¡¿ì½ºÀÇ °áÇÕ Á¶Á÷ ÃÊ
    ½Å°æ³»¸·, ƯÈ÷ ½Å°æ¼¶À¯ Á¾¸»Áö ÁÖÀ§ÀÇ ¾ãÀº ¿¬Àå.
  • crown and loop space maintainer
    Å©¶ó¿î¿£µå ·çÇÁÇü °£°Ý À¯Áö ÀåÄ¡
  • cultural and ethnic factor
    ¹®È­ ¹ÎÁ·Àû ¿äÀÎ
  • D and C ÀÚ±ÃÀÇ °æºÎ È®Àå°ú ³»¸· ¼ÒÆÄ.

    D factor

    D-ÀÎÀÚ
  • ear nose and throat
    À̺ñÀÎÈİú
    ÈĵÎ, ºñ°­, ÀεΠµîÀ» Àü¹®À¸·Î ÇÏ´Â ÀÇÇÐÀÇ ÇÑ ºÐ°ú.
  • exostosis and osteoma
    ¿Ü°ñÁõ ¹× °ñÁ¾
    »À Á¶Á÷ÀÇ °ú¹ßÀ°Àº Åë»ó ¿ì¿¬È÷ ¹ß°ßµÇ´Â °ÍÀÌ ´ëºÎºÐÀÌ°í °¡²û ÀÓ»óÀûÀ¸·Î Àǹ̰¡ ÀÖ´Â °æ¿ì¸¦ º»´Ù. ÀÓ»óÀûÀ¸·Î ÇǺηΠµ¤Èù µÕ±Ù °ñ Á¶Á÷ÀÌ ¿ÜÀ̵µÀÇ ³»Ãø¿¡¼­ °í¸·À» °¡¸®¸ç °üÂûµÈ´Ù. ÀϺο¡ ±¹ÇÑµÈ ´ÜÀÏÀÇ °ñÁ¾Àº ¿ÜÀ̵µ¸¦ ¿ÏÀüÈ÷ ¸·°Å³ª °¨¿°À» ÀÏÀ¸Å°Áö ¾Ê´Â ÇÑ ¹®Á¦°¡ ¾øÀ¸³ª ¶§·Î Â÷°¡¿î ¹°¿¡ Áö¼ÓÀûÀ¸·Î ³ëÃâµÈ °ÍÀÌ ¿øÀÎÀ¸·Î Áö¸ñµÇ±âµµ ÇÏ´Â ´Ù¹ß¼º °ñÁ¾ÀÇ °æ¿ì´Â Á¡Â÷ ÁøÇàµÇ¾î ¼ö¼úÀÌ ÇÊ¿äÇϱ⵵ ÇÏ´Ù.
  • explosion and fire hazard
    Æø¹ß ÀÎÈ­¼º À§Çè
  • Food and Drug Administration
    ½ÄǰÀǾà±â±¸
  • H and D curve
    Ư¼º °î¼±
  • habit and impulse disorder
    ½À°ü ¹× Ãæµ¿ Àå¾Ö, ½À°ü ¹× Ãæµ¿º´
  • hand and foot disease
    ¼Õ¹ß º´, ¼öÁ· º´
  • hand foot and mouth disease
    ¼öÁ·±¸ º´, ¼Õ¹ßÀÔ º´, ¼Õ¹ß ¹× ±¸°­ Áúȯ, ¼Õ-¹ß-±¸°­ Áúȯ
    1. ÄÛ»çŰ ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ »ý±ä µå¹® Àå ¹ÙÀÌ·¯½º¼º °¨¿° Áúȯ. 2. °æÁõÀ̳ª ´ë´ÜÈ÷ °¨¿°·ÂÀÌ ÀÖ´Â ¼Ò¾ÆÀÇ ¹ÙÀÌ·¯½º º´À¸·Î¼­, ÀÔ, ¼öÁ·¿¡ ¼öÆ÷¼º º´º¯À» º¼ ¼ö ÀÖ´Â °ÍÀÌ ±× Ư¡ÀÌ´Ù. 3. ÄÛ»çŰ ¹ÙÀÌ·¯½º A16ÀÇ °¨¿°À¸·Î ¼Õ, ¹ß, ÇÏÁö, ÀÔ¼Ó¿¡ ÀÛÀº ¼öÆ÷°¡ »ý±â´Â Áúº´. ÁÖ·Î Á¥¸ÔÀÌ¿¡°Ô Àß ³ªÅ¸³ª´Â °¨¿°ÁõÀε¥, 6°³¿ù ¹Ì¸¸ÀÇ Á¥¸ÔÀÌ¿Í 4¼¼ ÀÌ»óÀÇ ¾î¸°ÀÌ¿¡°Ô´Â µå¹°°Ô °¨¿°µÈ´Ù. ³²ÀÚ ¾î¸°ÀÌ¿¡°Ô ¸¹°í ¼ºÀο¡°Ôµµ ³ªÅ¸³­´Ù. ¿©¸§Ã¶¿¡ ÁÖ·Î ¹ßº´Çϰí 4~6Àϰ£ÀÇ Àẹ±â¸¦ °ÅÄ£´Ù. Áõ¼¼´Â ´ëü·Î °¡º±´Ù. 1957³â ij³ª´Ù Åä·ÐÅä¿¡¼­ À¯ÇàÇßÀ» ¶§ ·Îºó½¼ µîÀÌ ÀÌ Áõ¼¼¿¡ ´ëÇØ ±â·ÏÇß°í, ´º¿åÁÖ ÄÛ»çŰ¿¡¼­ óÀ½À¸·Î ÀÌ ¹ÙÀÌ·¯½º¸¦ ºÐ¸®½ÃŲ µ¥¼­ ±× Áö¹æ¸íÀ» µû¼­ ¸í¸íÇÏ¿´´Ù. ±× ´ç½Ã º´¿øÃ¼´Â ÄÛ»çŰ A16 ¹ÙÀÌ·¯½º¿´À¸³ª, ÈÄ¿¡ ÄÛ»çŰ A5, A10°ú ¿£Å×·Î ¹ÙÀÌ·¯½º 71Çü¿¡ ÀÇÇØ¼­µµ °°Àº Áõ¼¼ÀÇ º´ÀÌ ³ªÅ¸³­´Ù´Â °ÍÀÌ ¹àÇôÁ³´Ù. ÁÖ·Î ºñ¸» °¨¿°, °æ±¸ °¨¿°À¸·Î Àü¿°µÈ´Ù.
  • Harris and Ray test
    Ç츮½º-·¹ÀÌ ½ÃÇè
    ¿äÁßÀÇ ºñŸ¹Î C¿¡ ´ëÇÑ ¹Ì·® ÀûÁ¤¹ý.
  • head and neck cancer
    µÎ°æºÎ ¾Ï
    ¸Ó¸®¿Í ¸ñ ºÎÀ§¿¡ »ý±â´Â ¾Ï.
  • heat and cold therapy
    ³Ã¿Â ¿ä¹ý
    Â÷°¡¿î ÆÐµå¿Í ¶ß°Å¿î ÆÐµå¸¦ ¹ø°¥¾Æ°¡¸ç º´¼Ò¿¡ ´ë°í Ç÷¾× ¼øÈ¯À» ÃËÁø½Ã۰í ÅëÁõÀ» ¿ÏÈ­½ÃŰ´Â ¹æ¹ý.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
dental research The study of laws, theories, and hypotheses through a systematic examination of pertinent facts and their interpretation in the field of dentistry.
(12 Dec 1998)
operations research A group of techniques developed to apply scientific methods and tools to solve the problems of decision making in complex organizations and systems. Operations research searches for optimal solutions in situations of conflicting goals and makes use of mathematical models from which solutions for actual problems may be derived.
(12 Dec 1998)
epidemiologic research design The form and structure of analytic studies in epidemiologic and clinical research.
(12 Dec 1998)
united states office of research integrity An office of the united states public health service organised in june 1992 to promote research integrity and investigate misconduct in research supported by the public health service. It consolidates the office of scientific integrity of the national institutes of health and the office of scientific integrity review in the office of the assistant secretary for health. The ori is in the office of the assistant secretary for health and its director reports directly to the assistant secretary for health, department of health and human services. (ri newsletter, 1993 jan; 1(1):1)
(12 Dec 1998)
Bayley Scales of Infant Development A psychological test used to measure the developmental progress of infants over the first two and one-half years of life; consists of three scales: mental, motor, and behaviour record.
(05 Mar 2000)
bone development Gross development of bones from foetus to adult. It includes osteogenesis, which is restricted to formation and development of bone from the undifferentiated cells of the germ layers of the embryo. It does not include osseointegration.
(12 Dec 1998)
maxillofacial development The process of growth and differentiation of the jaws and face.
(12 Dec 1998)
child development The continuous sequential physiological and psychological maturing of the child from birth up to but not including adolescence. It includes healthy responses to situations, but does not include growth in stature or size (= growth).
(12 Dec 1998)
child development disorders, pervasive Severe distortions in the development of many basic psychological functions that are not normal for any stage in development. These distortions are manifested in sustained social impairment, speech abnormalities, and peculiar motor movements.
(12 Dec 1998)
personality development Growth of habitual patterns of behaviour in childhood and adolescence.
(12 Dec 1998)
pervasive development disorder <neurology, psychiatry> A large group of developmental disabilities which are neurological disorders, usually of unknown cause.
Characteristics include reduced abilities to understand language and communicate normally, reduced ability to socially interact with others in a normal manner, and limited variety in activities and interests. Individuals will also often respond in unusual ways to sensations, engage in repetitive activities, and resist changes to the environment or to daily routines.
Types of pervasive development disorder include autism, Retts Syndrome, Hellers Syndrome, and Aspergers Syndrome.
Acronym: PDD
(12 Jan 1998)
consensus development conference Designation for summary statements representing the majority and current agreement of physicians, scientists, and other professionals meeting to reach a consensus on a selected subject.
(12 Dec 1998)
consensus development conferences Presentations of summary statements representing the majority agreement of physicians, scientists, and other professionals convening for the purpose of reaching a consensus--often with findings and recommendations--on a subject of interest. The conference, consisting of participants representing the scientific and lay viewpoints, is a significant means of evaluating current medical thought and reflects the latest advances in research for the respective field being addressed.
(12 Dec 1998)
consensus development conferences, nih Articles on conferences sponsored by nih presenting summary statements representing the majority agreement of physicians, scientists, and other professionals convening for the purpose of reaching a consensus on a subject of interest. This heading is used for nih consensus conferences as a means of scientific communication. In indexing it is viewed as a type of review article and as a tag for any article appearing in any publication of the nih office of medical applications of research (omar).
(12 Dec 1998)
program development The process of formulating, improving, and expanding educational, managerial, or service-oriented work plans (excluding computer program development).
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • research worker
    =RESEARCHER
  • again and again
    ¹Ýº¹Çؼ­
  • and
    ±×¸®°í
  • and not ~ either
    ¶Ç ~ ¾Æ´Ï´Ù(=nor)
  • and so forth
    ±âŸ µîµî
  • and so on
    ..µîµî
  • and such
    µûÀ§,µîµî
  • and that
    ±×°Íµµ,°Ô´Ù°¡
  • both ~ and -
    ~ µµ - µµ (µÑ´Ù)
  • by and by
    ÀÌÀ¹°í
  • by-and-by
    ¹Ì·¡
  • checks and balances
    °ßÁ¦¿Í ±ÕÇü
  • every now and then
    À̵û±Ý
  • here and there
    ¿©±âÀú±â¿¡
  • hide-and-go-seek
    ¼û¹Ù²ÀÁú
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á